Startseite>>Signaling Pathways>> Neuroscience>> Ophthalmology>>Tafluprost (free acid)

Tafluprost (free acid) (Synonyms: AFP-172)

Katalog-Nr.GC40866

Tafluprost (freie SÄure) (AFP-172), eine aktive metabolische Form von Tafluprost, ist ein selektiver Prostanoid-FP-Rezeptoragonist.

Products are for research use only. Not for human use. We do not sell to patients.

Tafluprost (free acid) Chemische Struktur

Cas No.: 209860-88-8

Größe Preis Lagerbestand Menge
1mg
160,00 $
Auf Lager
5mg
718,00 $
Auf Lager
10mg
1.275,00 $
Auf Lager
25mg Please Inquire Please Inquire

Tel:(909) 407-4943 Email: sales@glpbio.com

Kundenbewertungen

Basiert auf Kundenrezensionen.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

A number of 17-phenyl trinor prostaglandin F2α (17-phenyl trinor PGF2α) derivatives have been approved for the treatment of glaucoma. Of these, the ones wherein the 13,14-double bond has been hydrogenated retain relatively good potency, but show a significantly reduced incidence of local irritant side effects. Alternatively, it was recently reported that analogs incorporating a 15-deoxy-15,15-difluoro modification also had a favorable ophthalmic activity profile. Tafluprost is a 2-series, 16-phenoxy analog of PGF2α with the 15,15-difluoro substitution. Tafluprost (free acid) is a very potent FP receptor agonist, with a Ki of 0.4 nM. The ester prodrug forms of tafluprost are also potent ocular hypotensives in monkeys.

Bewertungen

Review for Tafluprost (free acid)

Average Rating: 5 ★★★★★ (Based on Reviews and 7 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for Tafluprost (free acid)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.